Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.
Sun K, Zhang X, Lao M, He L, Wang S, Yang H, Xu J, Tang J, Hong Z, Song J, Guo C, Li M, Liu X, Chen Y, Zhang H, Zhou J, Lin J, Zhang S, Hong Y, Huang J, Liang T, Bai X.
Sun K, et al. Among authors: zhang s, zhang x, zhang h.
Mol Ther. 2023 Oct 4;31(10):2929-2947. doi: 10.1016/j.ymthe.2023.07.021. Epub 2023 Jul 28.
Mol Ther. 2023.
PMID: 37515321